1. Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation
- Author
-
M. Romero Cristóbal, Marcus-Alexander Wörns, R. Prince, L. Scuddeler, G. Sapisochin, M.L. González-Diéguez, Claudio Zavaglia, Helene Regnault, Maria Margarita Anders, Federica Invernizzi, Jordi Bruix, Giuliana Amaddeo, Lucia Cesarini, M. Reig, Álvaro Díaz-González, Matteo Angelo Manini, Matthias Pinter, Marco Sanduzzi-Zamparelli, M. Fraile-López, R. Tortora, Tommy Ivanics, Stefano Mazza, P. Daechul Yoon, Maria Francesca Donato, M.J. Blanco Rodríguez, Vincenzo Mazzaferro, Federico Piñero, M. Varela, Carolin Czauderna, Gonzalo Crespo, A. Fernandez Yunquera, Gerda Elisabeth Villadsen, Massimo Iavarone, G. Aballay Soteras, M. De Giorgio, Pietro Lampertico, G.G. Di Costanzo, Sherrie Bhoori, and Arndt Weinmann
- Subjects
Sorafenib ,Oncology ,medicine.medical_specialty ,Hepatology ,business.industry ,medicine.medical_treatment ,Gastroenterology ,Liver transplantation ,chemistry.chemical_compound ,chemistry ,Regorafenib ,Internal medicine ,medicine ,In patient ,business ,medicine.drug - Published
- 2021
- Full Text
- View/download PDF